S&CO Inc. Acquires New Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

S&CO Inc. bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 7,400 shares of the biopharmaceutical company’s stock, valued at approximately $2,227,000.

Several other large investors also recently added to or reduced their stakes in ALNY. Brighton Jones LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $243,000. Geneos Wealth Management Inc. increased its position in Alnylam Pharmaceuticals by 372.3% during the first quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 175 shares during the last quarter. Flow Traders U.S. LLC acquired a new position in Alnylam Pharmaceuticals during the second quarter worth $241,000. Daiwa Securities Group Inc. raised its holdings in Alnylam Pharmaceuticals by 0.3% during the second quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock valued at $4,220,000 after buying an additional 35 shares in the last quarter. Finally, NewEdge Advisors LLC raised its holdings in Alnylam Pharmaceuticals by 70,300.0% during the second quarter. NewEdge Advisors LLC now owns 704 shares of the biopharmaceutical company’s stock valued at $229,000 after buying an additional 703 shares in the last quarter. 92.97% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, Director David E. I. Pyott sold 3,830 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the sale, the director owned 1,582 shares in the company, valued at $473,302.76. This represents a 70.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Weiss Ratings raised Alnylam Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, July 31st. Barclays lowered their price objective on Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating on the stock in a report on Monday, August 3rd. Royal Bank Of Canada reduced their target price on Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating for the company in a report on Friday, July 31st. Chardan Capital reaffirmed a “buy” rating and set a $425.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, July 31st. Finally, Stifel Nicolaus dropped their price target on shares of Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating on the stock in a research report on Friday, July 31st. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $393.86.

Alnylam Pharmaceuticals Trading Up 0.7%

Shares of NASDAQ:ALNY opened at $228.65 on Friday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05. The stock’s 50-day moving average is $272.86 and its 200-day moving average is $301.44. The company has a market cap of $30.60 billion, a P/E ratio of 42.50 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 52-week low of $197.81 and a 52-week high of $495.55.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.